CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Revenue
Housing	$ 0	$ 268,582
Commercial rental - related party	0	0
Tissue array products	574,261	514,593
Total revenue	574,261	783,175
Cost of Sales
Housing	0	220,980
Commercial rental - related party	50,485	65,846
Tissue array products	339,925	329,089
Total cost of sales	390,410	615,915
Gross Profit	183,851	167,260
Operating Expenses:
Salaries and wages	228,526	233,124
Depreciation and amortization	121,954	149,925
Bad debt expense	2,895	330
(Reversal) Estimates of loss contingencies	0	(38,025)
Professional fees	74,924	77,408
Selling and distribution expenses	9,097	6,654
Other general and administrative expenses	288,780	169,594
Total Operating Expenses	726,176	599,010
Loss from Operations	(542,325)	(431,750)
Other Income (Expense)
Interest expenses	(220,979)	(194,592)
Other income (expense), net	148,767	(28,442)
Total Other Expense, Net	(72,212)	(223,034)
Loss before Income Taxes	(614,537)	(654,784)
Income Tax Expense	2,210	856
Net loss	(616,747)	(655,640)
Less: Net loss attributable to the non-controlling interests	(68,381)	(125,840)
Net loss attributable to CYBRDI, INC.	(548,366)	(529,800)
Foreign currency translation gain / (loss)	126,756	(10,362)
Comprehensive loss	$ (421,610)	$ (540,162)
Net Loss Per Common Share
Basic and Diluted	$ (0.01)	$ (0.01)
Weighted Average Number of Shares Outstanding
Basic and Diluted	120,225,323	120,225,323